Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXT007 versus factor VIII prophylaxis in congenital hemophilia A
PACTR202607757570833Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of zemocimig and Factor VIII in hemophilia A (2 arms), sponsored by Roche. Primary endpoint: Annualized Bleed Rate for treated bleeds. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
zemocimigFactor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on PACTR202607757570833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607757570833.